​
 

Frequently Asked Questions (FAQ)

 

A. Foundational Questions

Q: What is Neutral Lipid Storage Disease with Myopathy (NLSD-M)?
A: NLSD-M is a very rare genetic condition that affects the body's ability to process and store fat (lipids) in the muscles, leading to progressive muscle weakness.

​

Q: What is the difference between NLSD-M and Chanarin-Dorfman Syndrome (CDS)?
A: NLSD-M is often used interchangeably with CDS. Our organization specifically focuses on the myopathy (muscle weakness) and progressive aspects of the disease.

​

Q: What gene is associated with NLSD-M?
A: NLSD-M is caused by a mutation in the PNPLA2 gene.

​

Q: Is NLSD-M hereditary, and how is it inherited?
A: Yes, it is an autosomal recessive condition, meaning a child inherits a faulty gene from both parents who are typically carriers.
 

B. Symptoms and Diagnosis

Q: What are the first symptoms of NLSD-M in children or adults?
A: Primary symptoms include progressive muscle weakness (myopathy), often difficulty climbing stairs, and potential scaly skin/eye problems (ichthyosis).

​

Q: How is Neutral Lipid Storage Disease with Myopathy diagnosed?
A: Diagnosis involves a combination of a muscle biopsy (to show lipid accumulation), genetic testing specifically for the PNPLA2 gene mutation, and clinical assessment.
 

C. Treatment and Hope

Q: Is there a cure for Neutral Lipid Storage Disease with Myopathy?
A: Currently, there is no established cure, but our foundation is solely focused on funding cutting-edge research projects.

​

Q: What is the current status of NLSD-M gene therapy research?
A: Our funded research is actively advancing  in collaboration with our research partners. Please visit our Research page for the latest updates.

 

D. Support and Community

Q: How can I connect with other NLSD-M families?
A: Please visit our Community page to join our private online support groups and learn about our family conferences and gatherings.

​

Q: How can I donate to NLSD-M research?
A: You can donate directly on our secure donation page. 100% of funds go toward accelerating PNPLA2 gene therapy research efforts.
 

​

​